Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Completed
GlaxoSmithKline
Phase 2
2003-10-01
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of
an investigational drug for the treatment of constipation due to prescription pain medication
in subjects with cancer pain. The study will require five visits over a five-week period.
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
Completed
Cubist Pharmaceuticals LLC
Phase 2
2003-10-01
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of
an investigational drug for the treatment of constipation due to prescription pain medication
in subjects with cancer pain. The study will require five visits over a five-week period.
Study 767905/008 Extension Study: Alvimopan for Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects
Completed
GlaxoSmithKline
Phase 2
2004-09-01
Study SB-767905/008 was a multicenter study to evaluate the effectiveness and safety of
multiple dosage regimens of an investigational drug for the treatment of constipation due to
prescription pain medication in participants with cancer pain.
Study ABD101684 will serve as an extension to Study SB-767905/008 and offer continued access
to blinded investigational product to participants who have completed the original study. The
purpose of Study ABD101684 is to evaluate the safety and efficacy of alvimopan compared to
placebo in subjects who completed Study SB-767905/008 and elected to participate in this
extension study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
